logo

Brainstorm Cell Therapeutics Inc. (BCLI)



Trade BCLI now with
  Date
  Headline
8/5/2020 7:15:23 AM BrainStorm Cell Therapeutics Q2 Net Loss $7.39 Mln Vs. Net Loss $4.90 Mln Last Year
7/2/2020 6:56:59 AM BrainStorm Cell Therapeutics Completes All Dosing In NurOwn Phase 3 Clinical Trial In ALS; Expects Topline Data In Q4
7/1/2020 8:57:00 AM BrainStorm Plans To Showcase Alzheimer's Disease Clinical Program In KOL Webinar
6/23/2020 5:47:03 AM BrainStorm Cell Therapeutics To Join The Russell 2000® Index And Russell 3000® Index
6/2/2020 6:01:59 AM BrainStorm Says Pivotal Phase 3 Trial Remains On Track For Topline Data In Q4
5/27/2020 7:27:05 AM BrainStorm Appoints Stacy Lindborg As EVP, Head Of Global Clinical Research
4/3/2020 7:10:41 AM BrainStorm Cell Therapeutics Announces New Grant Of $1.5 Mln By The Israel Innovation Authority
3/31/2020 4:11:43 AM BrainStorm Names Jacob Frenkel Chairman Of Board
2/11/2020 6:11:18 AM BrainStorm Cell Therapeutics: FDA To Discuss Potential NurOwn Regulatory Pathways For Approval In ALS
1/29/2020 4:05:33 AM BrainStorm Gets Notice Of Intention To Grant Additional EU Patent For NurOwn
12/19/2019 5:07:30 AM BrainStorm: NurOwn DSMB Recommends MS Phase 2 Clinical Trial Continue
12/18/2019 5:09:51 AM BrainStorm Issues 2019 Letter To Shareholders; Says To Actively Seek Additional Opportunities To Expand Its Pipeline
11/25/2019 6:08:46 AM BrainStorm Announces Mount Sinai Medical Center As A Progressive MS Phase 2 Clinical Trial Site
10/11/2019 1:04:16 AM BrainStorm Cell Therapeutics Says Fully Enrolls 200-patient Phase 3 Clinical Trial Of NurOwn Cellular Therapeutic In ALS
10/7/2019 8:04:52 AM BrainStorm Announces Notice Of US Patent Allowance For NurOwn Cellular Therapeutic Technology Platform